biospecimen banks

CPDR Patient Education Program

Industry-Sponsored Clinical Trials and Projects

The CRC maintains a comprehensive portfolio of both investigator-initiated and industrysponsored clinical trials that cover the entire patient's "life cycle." Some of the trials, though industry sponsored, were investigator-initiated trials for which a proposal was submitted by CPDR to obtain funding. There are two types of these studies:

  • One is when we approach the industry with a proposal and request funding under a collaborative type of agreement; the ownership and control remains with CPDR but costs are supported by the company. One example of this is the CPDR Prostate Cancer Quality of Life Study that has been ongoing since 2003 and has a current enrollment of more 1,600 men. This study is a unique asset to the program in that it looks at patient-reported outcomes; however, it is a very costly endeavor due to its labor intensiveness. The study includes administration of the EPIC questionnaire along with the SF-36v2® health questionnaire to men newly diagnosed with prostate cancer at baseline (before treatment), and at eight other time points subsequent to their treatment for three years. After submission of a proposal to GlaxoSmithKline, it was accepted by the company for funding on a year-to-year basis and has thus far received approval for three years of funding.

  • The other type of study is to take an idea to a company for another application or therapeutic target using that company's existing technology. This approach usually results in work being conducted under a traditional clinical trial agreement where CPDR conducts the study, is reimbursed for the time spent working on the trial, and the data are supplied to the company who uses their resources for analysis.

  • All trials and projects are carried out with full approval of the respective IRBs.

 

Current Clinical Trials

1. A Multicenter Clinical Study of the Sonablate®500 for the Treatment of Locally Recurrent Prostate Cancer With HIFU - Click Here for Information on the Trial

2. Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer
Click Here for Information on the Trial

3. - A Phase 3 Efficacy Study of a Recombinant Vaccinia Virus Vaccine to Treat Metastatic Prostate Cancer
Click Here for Information on the Trial

 

CURRENT EVENTS


September 29, 2014

Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as Predictor of Near- and Long-term Outcomes in Racially Diverse Group of Prostate Cancer Patients

REDWOOD CITY, CA – Genomic Health, Inc. (Nasdaq: GHDX) today announced strongly positive results from an additional independent clinical validation study of the Oncotype DX® prostate cancer test, conducted in collaboration with the Uniformed Services University of the Health Sciences' (USU) Center for Prostate Disease Research (CPDR) supported by a multi-disciplinary team of investigators under a cooperative research and development agreement with USU. This new large study reconfirmed the biopsy-based test's Genomic Prostate Score (GPS) as a predictor of adverse pathology at surgery and, for the first time, validated GPS as a strong independent predictor of a rise in prostate-specific antigen (PSA) following surgery (biochemical recurrence).

Read Full Article

 

WRNMMC UsToo!
Quarterly Guest Speakers

Dr. Valencia Clay
Palliative Care Physician, WRNMMC

Dr. Jerry Waddell
Psychologist and Program Director of the Palliative Care Service, WRNMMC

Presentation: "Quality of Life in Disease Progression"

Free and no registration required.

Date: Thursday, 6 November 2014
Time: 7-8:30 PM
Location: America Building, 2nd floor, Room 2525
(above the lab/pharmacy) and Fort Belvoir Community Hospital
(Oaks Pavilion, 1st floor, Room 332)
by videoteleconference.
Contact: COL (ret) Jane Hudak for more information at 301-319-2918 or
jane.l.hudak.ctr@health.mil

Read the NOVEMEBR 2014 Newsletter